Inspire Veterinary Partners, Inc. Class A (IVP) AI Stock Analysis

• Market Cap: $1.98M
• Dividend Yield: N/A
• Average Volume (3M): 44.35M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.85
• Revenue Growth: -8.76%
• EPS Growth: 99.64%
• Country: US
• Employees: 113
• Sector: Consumer Cyclical
• Sector Strength: 84
• Industry: Personal Products & Services
• EPS (TTM): -0.41
• Shares Outstanding: 38,567,467
• 10 Day Avg. Volume: 132,839,515
• 30 Day Avg. Volume: 44,350,689
• PEG Ratio: <0.01
• Price to Book (P/B): 0.67
• Price to Sales (P/S): 0.06
• P/FCF Ratio: -0.10
• Enterprise Value/Market Cap: 10.21
• Enterprise Value/Revenue: 1.30
• Enterprise Value/Gross Profit: 4.26
• Enterprise Value/Ebitda: -2.41
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 37 Underperform
• Price Target: $0.00 ▼(-100.00% Downside)

Inspire Veterinary Partners, Inc. is facing severe financial and operational challenges. The high leverage, negative profitability, and bearish technical indicators contribute to a low stock score. The potential Nasdaq delisting adds further risk, overshadowing any positive developments.

Positive Factors

Revenue Sharing Agreements

Revenue sharing agreements provide a steady income stream, aligning incentives with partner clinics and potentially enhancing long-term revenue growth.

Partnerships with Pharmaceutical Companies

These partnerships enhance service offerings and streamline costs, providing a competitive advantage and supporting sustainable revenue growth.

Operational Support Services

Providing operational support services strengthens partner clinics, potentially improving their efficiency and profitability, which benefits IVP's revenue.

Negative Factors

High Leverage

High leverage can strain financial flexibility, increasing risk and potentially impacting the company's ability to invest in growth opportunities.

Nasdaq Delisting Threat

The delisting threat poses significant risk, potentially reducing investor confidence and limiting access to capital markets, affecting long-term growth.

Negative Profitability

Negative profitability highlights operational challenges, potentially hindering reinvestment in the business and affecting long-term sustainability.

Inspire Veterinary Partners, Inc. Class A Business Overview & Revenue Model

Company Description

Inspire Veterinary Partners, Inc. owns and operates veterinary hospitals in the United States. The company specializes in small animal general practice hospitals, which serve companion pets, canine, and feline breeds. Its hospitals provide preventive care for companion animals consisting of annual health exams and parasite control; dental health; nutrition and body condition counseling; neurological examinations; radiology; bloodwork; and skin and coat health, and other breed specific preventive care services. The company also provides surgical services, which include soft tissue procedures, such as spays and neuters, mass removals, splenectomies, gastropexies, orthopedic procedures, and other surgical offerings; and care and alternative procedures, such as acupuncture, chiropractic, and other health and wellness services. Inspire Veterinary Partners, Inc. was incorporated in 2020 and is based in Virginia Beach, Virginia.

How the Company Makes Money

Inspire Veterinary Partners generates revenue primarily through a combination of service fees from partnered veterinary practices and a percentage of the profits from these practices. The company charges management fees for its operational support services, which may include marketing, financial management, and staff training. Additionally, IVP benefits from revenue sharing agreements, where it receives a portion of the profits from the veterinary clinics it partners with. Significant partnerships with pharmaceutical and pet care companies also contribute to its earnings through collaborative marketing efforts and supply chain agreements, allowing IVP to enhance its service offerings and streamline costs.

Inspire Veterinary Partners, Inc. Class A Financial Statement Overview

Summary

Inspire Veterinary Partners, Inc. faces significant challenges in profitability and financial stability. The company has shown slight revenue growth, but high leverage, negative margins, and poor cost management are major concerns. Improving operational efficiency and reducing debt are crucial for enhancing financial performance.

Income Statement

Inspire Veterinary Partners, Inc. has shown a slight revenue growth in the TTM period, but profitability remains a concern with negative net profit and EBIT margins. The gross profit margin has decreased compared to the previous year, indicating pressure on cost management. The company needs to improve its operational efficiency to enhance profitability.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio, indicating significant leverage and potential financial risk. The negative return on equity highlights challenges in generating returns for shareholders. The equity ratio is low, suggesting reliance on debt financing. Improving equity and reducing debt could stabilize the financial structure.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, with a declining free cash flow growth rate. However, the free cash flow to net income ratio is positive, indicating some efficiency in converting net income to cash. Enhancing cash flow generation is crucial for financial health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	15.56M	16.59M	16.68M	9.83M	2.55M	0.00
Gross Profit	4.73M	3.29M	3.55M	2.55M	829.29K	0.00
EBITDA	-8.36M	-9.50M	-10.84M	-2.91M	-977.46K	0.00
Net Income	-11.94M	-14.26M	-14.79M	-4.91M	-1.33M	-5.52K
Balance Sheet
Total Assets	23.96M	20.20M	21.79M	20.19M	6.33M	21.97K
Cash, Cash Equivalents and Short-Term Investments	341.75K	523.69K	178.96K	444.25K	2.06M	21.97K
Total Debt	13.94M	16.37M	18.42M	23.61M	6.69M	0.00
Total Liabilities	19.79M	18.63M	22.58M	25.32M	7.20M	0.00
Stockholders Equity	4.17M	1.56M	-788.26K	-5.14M	-869.09K	21.97K
Cash Flow
Free Cash Flow	-4.34M	-10.24M	-4.20M	-2.84M	-2.32M	-5.52K
Operating Cash Flow	-4.23M	-10.01M	-3.82M	-2.66M	-1.01M	-5.52K
Investing Cash Flow	-1.96M	-237.98K	-1.87M	-14.67M	-4.02M	0.00
Financing Cash Flow	5.89M	10.59M	5.63M	15.71M	7.07M	269.16K

Inspire Veterinary Partners, Inc. Class A Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IVP, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.09, below the 50-day MA of 0.50, and below the 200-day MA of 1.10, indicating a bearish trend. The MACD of -0.12 indicates Negative momentum. The RSI at 20.02 is Positive, neither overbought nor oversold. The STOCH value of 13.24 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IVP.

Inspire Veterinary Partners, Inc. Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$18.38B	12.79	-2.54%	3.03%	1.52%	-15.83%
MRM	58 Neutral	$16.83M	5.82	48.22%	―	13.71%	―
EJH	40 Neutral	$45.36M	-0.02	-1.75%	―	-2.53%	99.45%
XWEL	40 Underperform	$3.78M	-0.21	―	―	-12.74%	13.22%
IVP	37 Underperform	$1.98M	-0.01	-331.80%	―	-8.76%	99.64%

Inspire Veterinary Partners, Inc. Class A Corporate Events

Inspire Veterinary Partners Signs Consulting Agreement for Growth

On December 12, 2025, Inspire Veterinary Partners, Inc. entered a Consulting Agreement with 622 Capital LLC to receive business development services aimed at business financing opportunities. As part of this agreement, the company will issue an aggregate of 9,450,000 shares of its Class A common stock to the consultant, impacting the company’s equity structure. The agreement will remain effective under standard provisions until terminated, reflecting efforts to enhance Inspire Veterinary Partners’ financial positioning and strategic growth.

Inspire Veterinary Partners Holds Annual Stockholders Meeting

On December 10, 2025, Inspire Veterinary Partners, Inc. held its Annual Meeting of Stockholders, where key decisions were made regarding the company’s governance and financial oversight. The stockholders elected directors to the board for terms expiring at the 2026 annual meeting, and ratified the appointment of M&K CPAS, PLLC as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions are expected to influence the company’s strategic direction and financial management.

Inspire Veterinary Partners Amends Promissory Notes and Stock Terms

Inspire Veterinary Partners, Inc. announced on December 1, 2025, a reduction in the Floor Price of its Series B Convertible Preferred Stock from $0.1879 to $0.05 per share, following agreements with accredited investors. Additionally, the company redeemed 2,027 shares of Series B Preferred Stock for approximately $2.7 million. On December 4, 2025, the company also amended promissory notes with Target Capital 1 LLC to lower the Floor Price and restrict conversion to prevent exceeding 4.99% ownership of the company’s Class A common stock.

Inspire Veterinary Faces Nasdaq Delisting Threat

Inspire Veterinary Partners, Inc. has received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement, threatening suspension and delisting of its securities. The company has requested a hearing, scheduled for January 13, 2026, to appeal this decision, but there is no assurance of a favorable outcome.

Inspire Veterinary Faces Nasdaq Delisting Notice

On November 13, 2025, Inspire Veterinary Partners, Inc. received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement due to its stock’s performance over the past 30 days. As a result, the company’s securities are set to be suspended from trading on November 24, 2025, unless an appeal is requested by November 20, 2025. The company plans to appeal, which will delay the suspension or delisting process, but there is no guarantee of a favorable outcome.

Inspire Veterinary Partners Issues Convertible Notes for Capital

On November 5, 2025, Inspire Veterinary Partners, Inc. issued Senior Convertible Promissory Notes to Keystone Capital Partners, LLC and Seven Knots, LLC, each with a principal amount of $178,571.43. The notes, which mature on August 5, 2026, include a 10% annual interest rate and are convertible into the company’s Class A common stock. This financial maneuver is aimed at bolstering the company’s working capital, with specific terms allowing for conversion and prepayment under certain conditions, potentially impacting the company’s financial strategy and shareholder structure.